Latest filing published 27 Dec 2023 for Moleculin Biotech, Inc., €9,074.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -85.3%Entry US$281.25 · Close at T+365 US$41.25
- +104.5%Entry US$40,049.86 · Close at T+365 US$81,899.71
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Robert E. George: trading record in brief
All filings by Robert E. George on record concern Moleculin Biotech, Inc. We count 2 filings; the first trade dates from 28 April 2017 and the latest from 26 December 2023.
No open-market sale appears; the market trades are 2 purchases worth €9,938. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2023, the count stands at 1 purchase and no sales.
The record was last updated on 27 December 2023 with an open-market purchase (€9,074) in Moleculin Biotech, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Robert E. George
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 14,493 shares@ US$0.69100.0% of flowCommon StockSEC:0001437749-23-035341:0Canonical exit: 25 Mar 2024 (T+90)
- 1,000 shares@ US$0.93848.7% of flowCommon StockSEC:0001144204-17-023240:0Canonical exit: 27 Jul 2017 (T+90)
2 of 2 declarations
